Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Triazolam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 5/20 | 0.71 |
| ▸ | GABRA5 known ✓ | P31644 | 5/20 | 0.71 |
| ▸ | GABRA2 known ✓ | P47869 | 5/20 | 0.71 |
| ▸ | GABRA3 known ✓ | P34903 | 4/20 | 0.71 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.71 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.71 |
| ▸ | GABRB2 known ✓ | P47870 | 4/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.71 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | PTAFR | P25105 | 8/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alprazolam SCHEMBL625827 | 0.91 | GABRA1 (0.71) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL5142333 | 0.84 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29349744 | 0.84 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29368430 | 0.84 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29382425 | 0.84 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL29228 | 0.84 | GABRA1 (1.00) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL9055695 | 0.83 | GABRA1 (0.98) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL27600059 | 0.83 | GABRA1 (0.98) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Brotizolam SCHEMBL5672939 | 0.83 | PTAFR (0.72) | GABRA1GABRA5GABRA2GABRA3OPRK1 | |
| Triazolam SCHEMBL3262516 | 0.80 | GABRA1 (0.86) | GABRA1GABRA5GABRA2GABRA3OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0386232-B2 | NASAL ADMINISTRATION OF BENZODIAZEPINE HYPNOTICS | RIBOGENE INC (US) | 2000-09-06 | — | — | EP | claimed |
| EP-4171555-A1 | METHODS FOR TREATING BENZODIAZEPINE MISUSE/USE DISORDER | University of Mississippi Medical Center (US) | 2023-05-03 | — | — | EP | disclosed |
| WO-2022006290-A1 | METHODS FOR TREATING BENZODIAZEPINE MISUSE/USE DISORDER | UNIVERSITY OF MISSISSIPPI MEDICAL CENTER (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210401849-A1 | METHODS FOR TREATING BENZODIAZEPINE MISUSE/USE DISORDER | NATIONAL INSTITUTES OF HEALTH | 2021-12-30 | — | — | US | disclosed |
| EP-2604257-B1 | Oral transmucosal dosage forms comprising sufentanil and triazolam | ACELRX PHARMACEUTICALS INC (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2182902-B1 | COMPOSITIONS COMPRISING SUFENTANIL AND TRIAZOLAM FOR PROCEDURAL SEDATION AND ANALGESIA USING ORAL TRANSMUCOSAL DOSAGE FORMS | ACELRX PHARMACEUTICALS INC (US) | 2015-01-07 | — | — | EP | disclosed |
| EP-1494650-B1 | PHARMACEUTICAL FORMULATION COMPRISING MELATONIN | NEURIM PHARMA 1991 (IL) | 2011-05-04 | — | — | EP | disclosed |
| EP-1494650-A4 | PHARMACEUTICAL FORMULATION COMPRISING MELATONIN | NEURIM PHARMA 1991 (IL) | 2006-07-12 | — | — | EP | disclosed |
| US-20050175692-A1 | For use in short-term potentiation of the effects of non-barbiturate and non-benzodiazepine hypnotics such as zaleplon, zolpidem, zopiclone and trazodone on sedation and psychomotor skills; prevents drug dependence | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2005-08-11 | — | — | US | disclosed |
| EP-1494650-A1 | PHARMACEUTICAL FORMULATION COMPRISING MELATONIN | NEURIM PHARMACEUTICALS (1991) LIMITED (IL) | 2005-01-12 | — | — | EP | disclosed |
| WO-2003086352-A1 | PHARMACEUTICAL FORMULATION COMPRISING MELATONIN | NEURIM PHARMACEUTICALS (1991) LTD. (IL) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401849-A1 | METHODS FOR TREATING BENZODIAZEPINE MISUSE/USE DISORDER | GABBR1, GABRB3, GABBR2 | GABRA1 9/4885GABRA5 12/4885GABRA2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.